In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

There has also been a surge in demand for weight loss jabs after a number of ... the first patients to receive Wegovy from the NHS, a medication containing semaglutide that is approved for weight ...